What's New

Last Posted: Jul 18, 2024

• A roadmap for affordable genetic medicines
  
• A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization among Patients with Sickle Cell Disease.
  Cameron Roessner et al. Adv Hematol 2024 20244753349
• Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.
  Lydia H Pecker et al. Expert Rev Hematol 2024
• [Sickle cell disease in French Guiana: assessing 30 years of neonatal screening (1992-2021)].
  Narcisse Elenga et al. Med Trop Sante Int 2024 4(1)
• Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis.
  Priscilla Peter Dilli et al. BMC Public Health 2024 24(1) 1467
• A Mixed-Methods Evaluation of a Project ECHO Program for the Evidence-Based Management of Sickle Cell Disease.
  Cami Mosley et al. Int J Environ Res Public Health 2024 21(5)
• Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
  Mariam Barak et al. Cells 2024 13(10)
• Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana.
  Samuel T Chatio et al. PLoS One 2024 19(5) e0303520
• The highest-cost Medicaid enrollees with sickle cell disease had annual health care expenditures nearing $200 000.
  Junelle Speller et al. Health Aff Sch 2024 2(4) qxae029
• A national postgraduate nurse practitioner and physician assistant fellowship in cystic fibrosis: An innovative approach to the provider shortage in complex and rare disease.
  Cynthia J Brady et al. J Am Assoc Nurse Pract 2024
• Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-Modifying and Potentially Curative Therapies.
  Luisanna M Sánchez et al. J Pediatr Hematol Oncol 2024
• Determination of birth prevalence of sickle cell disease using point of care test HemotypeSC™ at Rundu Hospital, Namibia.
  Runyararo Mashingaidze Mano et al. BMC Pediatr 2024 24(1) 323
• Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
  William L Herring et al. Pharmacoeconomics 2024
• Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortality.
  Caroline Vuong et al. Am J Hematol 2024
• Exagamglogene Autotemcel for Severe Sickle Cell Disease
  
• Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes.
  Tsung-Ling Lee et al. Front Genet 2024 151381172
• Translational Research and Health Equity: Gene Therapies for Sickle Cell Disease as a Case Study.
  Mary A Majumder et al. Ethics Hum Res 2024 46(3) 34-39
• Impact of Race, Socioeconomic Status, and Geography on Healthcare Outcomes for Children With Sickle Cell Disease in the United States: A Scoping Review
  
• Awareness of sickle cell disease among nursing undergraduates in Farasan: Its interference with malaria.
  Shabihul Fatma Sayed et al. J Family Med Prim Care 2024 13(2) 589-599
• Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.
  Jennifer Davila et al. Br J Haematol 2024
• Current Methods of Newborn Screening Follow-Up for Sickle Cell Disease Are Highly Variable and without Quality Assurance: Results from the ENHANCE Study.
  Najibah Galadanci et al. Int J Neonatal Screen 2024 10(1)
• Iowa Newborn Screening Program Experience with Hemoglobinopathy Screening over the Last Two Decades and Its Increasing Global Relevance.
  Ryan Jilek et al. Int J Neonatal Screen 2024 10(1)
• Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020.
  Mariam Kayle et al. MMWR Morb Mortal Wkly Rep 2024 3 (12) 248-254
• A scoping review exploring cure definitions and language for inherited hemoglobinopathies.
  Marilyn S Baffoe-Bonnie et al. Genet Med Open 2024 2
• An International Learning Collaborative Phase 2 Trial for Haploidentical Bone Marrow Transplant in Sickle Cell Disease.
  Adetola A Kassim et al. Blood 2024
• Current state of gene therapy in sickle cell disease.
  Mei San Tang et al. Vox Sang 2024
• Dental caries in the permanent dentition and health-related quality of life among children and adolescents with sickle cell disease.
  Vera Lúcia Duarte da Costa Mendes et al. Cien Saude Colet 2024 29(3) e06752023
• Genetic Information to Share with Parents when Newborn Screening Reveals the Presence of Sickle Cell Trait.
  Narcisse Elenga et al. Int J Pediatr 2024 20248910397
• Perceptions and preferences for genetic testing for sickle cell disease or trait: a qualitative study in Cameroon, Ghana and Tanzania.
  Nchangwi Syntia Munung et al. Eur J Hum Genet 2024
• Patient Perceptions on the Advancement of Noninvasive Prenatal Testing for Sickle Cell Disease among Black Women in the United States.
  Shameka P Thomas et al. AJOB Empir Bioeth 2024 1-10

More